Mya C Schiess (McGovern Medical School at UTHealth, Houston, TX, USA) discusses promising findings from a phase I study (ClinicalTrials.gov identifier: NCT02611167), which was the focus of her presentation entitled: Allogeneic bone marrow-derived mesenchymal stem cells safety and tolerability in idiopathic Parkinson’s disease.
Questions
1. What is known about the role of inflammation in the pathogenesis of Parkinson’s disease (PD)? (0:06)
2. What is the rationale for the use of mesenchymal stem cells as immunomodulatory therapy in people with PD? (2:04)
See also the 2nd part of this interview here.
Disclosures: Prof. Mya Schiess is the principal investigator of the study discussed in this video interview, which was sponsored by philanthropic support to the Regenerative Movement Disorders Fund and conducted at The University of Texas Health Science Center, Houston, TX, USA.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the International Parkinson and Movement Disorder Society MDS Virtual Congress 2020.
